Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $202,950.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $27.06, for a total value of $202,950.00. Following the completion of the sale, the insider directly owned 32,316 shares in the company, valued at $874,470.96. The trade was a 18.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $84,350.43.
• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total value of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.34, for a total value of $205,050.00.

Maze Therapeutics Price Performance

MAZE opened at $26.43 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock has a market capitalization of $1.47 billion, a PE ratio of -10.49 and a beta of 2.16. The stock’s 50 day moving average price is $26.97 and its 200-day moving average price is $28.22. Maze Therapeutics, Inc. has a 52-week low of $21.95 and a 52-week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, equities research analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. increased its stake in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after acquiring an additional 465,641 shares in the last quarter. TRV GP IV LLC bought a new stake in Maze Therapeutics during the second quarter worth about $133,502,907. ARCH Venture Management LLC purchased a new stake in Maze Therapeutics in the second quarter worth about $122,983,582. BlackRock Inc. purchased a new stake in Maze Therapeutics in the second quarter worth about $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics during the second quarter valued at approximately $101,764,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Citigroup started coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price for the company. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and a consensus price target of $63.40.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.